
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Axsome Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will earn ($0.41) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share.
Other analysts have also issued research reports about the company. Wells Fargo & Company restated an "overweight" rating and issued a $165.00 price objective (up previously from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 6th. Royal Bank of Canada dropped their price target on shares of Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating for the company in a research report on Thursday. Needham & Company LLC cut their target price on Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating for the company in a research report on Monday. Morgan Stanley raised their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Finally, Truist Financial boosted their price target on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $172.33.
Get Our Latest Report on AXSM
Axsome Therapeutics Stock Down 2.0%
Shares of NASDAQ AXSM traded down $2.15 during trading hours on Tuesday, hitting $104.10. The company had a trading volume of 425,883 shares, compared to its average volume of 676,588. Axsome Therapeutics has a 1-year low of $71.15 and a 1-year high of $139.13. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The firm's 50 day moving average is $106.45 and its 200-day moving average is $106.95. The stock has a market capitalization of $5.13 billion, a P/E ratio of -17.38 and a beta of 0.47.
Insider Transactions at Axsome Therapeutics
In other Axsome Therapeutics news, Director Mark Coleman sold 3,750 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total value of $395,512.50. Following the sale, the director now owns 50,387 shares in the company, valued at $5,314,316.89. This trade represents a 6.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Mark L. Jacobson sold 25,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $110.44, for a total transaction of $2,761,000.00. Following the transaction, the chief operating officer now owns 5,783 shares of the company's stock, valued at $638,674.52. This trade represents a 81.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,423 shares of company stock valued at $7,711,619. 22.30% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Axsome Therapeutics
Hedge funds have recently modified their holdings of the company. Strategic Financial Concepts LLC acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $2,599,000. Principal Financial Group Inc. grew its holdings in Axsome Therapeutics by 6,002.7% during the 4th quarter. Principal Financial Group Inc. now owns 207,065 shares of the company's stock worth $17,520,000 after acquiring an additional 203,672 shares during the last quarter. Peregrine Capital Management LLC increased its position in Axsome Therapeutics by 21.2% in the 4th quarter. Peregrine Capital Management LLC now owns 87,187 shares of the company's stock valued at $7,377,000 after acquiring an additional 15,258 shares during the period. New York State Common Retirement Fund raised its stake in shares of Axsome Therapeutics by 64.8% during the fourth quarter. New York State Common Retirement Fund now owns 22,491 shares of the company's stock valued at $1,903,000 after acquiring an additional 8,843 shares during the last quarter. Finally, IFP Advisors Inc raised its stake in shares of Axsome Therapeutics by 36.2% during the fourth quarter. IFP Advisors Inc now owns 67,839 shares of the company's stock valued at $5,740,000 after acquiring an additional 18,038 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.
About Axsome Therapeutics
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Read More

Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.